Compare VREX & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | RZLT |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 420.8M |
| IPO Year | 2016 | 2011 |
| Metric | VREX | RZLT |
|---|---|---|
| Price | $10.98 | $4.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.67 | $9.67 |
| AVG Volume (30 Days) | 466.3K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $811,000,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $1.07 |
| 52 Week High | $14.57 | $11.46 |
| Indicator | VREX | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 57.73 | 53.68 |
| Support Level | $10.88 | $2.91 |
| Resistance Level | $12.62 | $5.42 |
| Average True Range (ATR) | 0.47 | 0.35 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 80.33 | 61.35 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.